Posts

In a recent ISB Research Roundtable, ISB President Dr. Jim Heath shared new findings connecting Long COVID to immune dysfunction and autoimmune diseases, and explained how artificial intelligence could accelerate the search for answers — and potentially new treatments — for millions of people living with the condition.

By integrating single-cell, proteomic, genetic, clinical, and laboratory data, the team found that these cells adopt molecular features also seen in established autoimmune diseases. The findings help explain how viral infections can disrupt immune regulation and may provide a framework for understanding and eventually preventing autoimmune complications following infection.

Researchers at the Institute for Systems Biology have developed a powerful new platform that can identify and deeply profile antigen-specific CD4+ T cells at unprecedented scale and resolution. Published in Nature Communications, the work could help accelerate vaccine design, improve immune monitoring, and advance next-generation cancer immunotherapies.

ISB researchers reveal a darker side of targeted therapy: the same oncogene inhibition that shuts down cancer growth program can also ignite a stress-driven identity switch — revealing an early escape route that may shape the future of cancer treatment

Whitney Gibb used to move through life at full speed. After COVID, brain fog, fatigue, and memory loss reshaped her daily life — offering a powerful window into the realities of Long COVID and the research now working to understand it.

ISB has won a 2025 AWS Imagine Grant to advance Tarpon, a generative AI platform that generates digital fingerprints of T cell receptors. By linking immune signatures to genomic and clinical data, Tarpon enables rapid discovery and the design of targeted therapies.